CDBIO(SH:688739) Zheng Quan Ri Bao Zhi Sheng·2025-12-02 12:36Core Insights - Chengda Biotech is developing a biotechnology product research and production base, which is planned in two phases [1] - The first phase includes the production workshop for a 15-valent HPV vaccine, while the second phase will consist of standardized biological product facilities [1] - The 15-valent HPV vaccine is currently in Phase II clinical trials, and the progress of vaccine development and project construction is subject to various uncertainties [1] Summary by Categories - Project Development - The biotechnology product research and production base is structured in two phases [1] - Phase one includes facilities for the 15-valent HPV vaccine production [1] - Phase two will focus on standardized biological product manufacturing [1] - Vaccine Development Status - The 15-valent HPV vaccine is in Phase II clinical trials [1] - The approval process for the vaccine and project construction faces multiple influencing factors, leading to uncertainties [1] - The company commits to timely disclosures regarding any significant updates [1]